2020 PRESENTING COMPANIES
August 20th, 2020 at the following times:
10:00 am - 12:00 noon Pacific Time
1:00 - 3:00 pm Eastern Time
20/20 OptimEyes Technologies
C20/20 is the new Innovation Hub at McMaster University in Hamilton, Canada. Our first spin out company, OptimEyes Technologies, has developed an innovative topical approach improving the sustained effect of therapeutics targeted initially for dry eye disease. Our first product is an aqueous, micelle technology mucoadhesive formulation with a higher-dose cyclosporine A drop that can relieve symptoms when administered twice a week, with the potential for once a week treatment. This allows patients to put in drops comfortably and less frequently, improving patient compliance and so potentially increasing clinical outcomes to improve their vision. Multiple strategic opportunities exist for additional therapeutics with this novel micelle technology.
AdOM Advanced Optical Technologies
Founded in 2008, AdOM is an ophthalmic medical device startup developing a novel diagnostic imaging device, the Tear Film Imager (TFI), which measures the Tear Film dynamics in nanometer resolution. The TFI is the only device capable of measuring both the aqueous & lipid sublayers simultaneously.
The TFI will revolutionize dry eye disease management by offering comprehensive diagnostics of dry eye parameters in a 40 second noninvasive test. Based on artificial intelligence and hyperspectral imaging the TFI provides quantitative representative parameters of the tear film as proven in clinical studies.
AdOM will launch the TFI in the U.S. market upon FDA registration in the 1H of 2020. This device will easily fit into clinical office-based practices as a leading tool for diagnosing dry eye disease.
Eyedetec Medical is developing a novel, office and home based therapy for MGD. Our product is much easier to use than other technologies, is extremely soothing and comfortable for the patient, and is significantly less expensive than any other approach. We have strong IP with FTO confirmed, positive proof-of-concept clinical data, plans for a multi-center clinical study, low-risk regulatory pathway, and a strong team of executives and physician advisors. We are raising a $5M Series A equity round, and anticipate having a commercial ready product within 15 months of funding.
Kala is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye. Kala has applied its proprietary AMPPLIFY Drug Delivery Technology to a corticosteroid, loteprednol etabonate (LE), designed for ocular applications, resulting in the August 2018 FDA approval of INVELTYS® for the treatment of inflammation and pain following ocular surgery and its lead product candidate, EYSUVIS® (KPI-121 0.25%), for the temporary relief of the signs and symptoms of dry eye disease. Kala recently reported positive Phase 3 results for EYSUVIS, which may enable a potential approval and launch by year-end 2020.
Novaliq is a pharmaceutical company focusing on the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol®, the worldwide first water-free eye drop technology. Novaliq offers an industry-leading portfolio addressing today’s unmet needs of millions of patients with eye diseases. Novaliq is headquartered in Heidelberg, Germany and has an office in Cambridge, MA, USA. The long-term shareholder is dievini Hopp BioTech holding gmbH & Co. KG, an active investor in Life and Health Sciences companies.
Ocunova is a biotech company focused exclusively on development of a new treatment for Dry Eye Syndrome. The company is raising capital to support a phase 2 efficacy study of its novel treatment for Dry Eye.
Olympic Ophthalmics is a venture backed start-up company dedicated to developing novel treatments for dry eye disease. The investors, board, and management have deep expertise in medical device technology development. Its first regulatory approval and offering is a neurostimulation device to increase tear production by gentle stimulation of the external nasal nerve.
Tarsus Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on the development and commercialization of first-in-class therapeutic candidates to address large market opportunities initially in ophthalmic conditions where there are limited treatment alternatives, starting with Demodex blepharitis. Tarsus was founded in 2017 and is headquartered in Irvine, California.